On May 10, 2024, the United States Patent and Trademark Office (“USPTO”) published a notice of proposed rulemaking in the Federal Register that could dramatically impact prosecution practices, especially for those...more
5/20/2024
/ Double Patent ,
Life Sciences ,
Obviousness ,
Patent Applicants ,
Patent Applications ,
Patent Litigation ,
Patents ,
Proposed Rules ,
Public Comment ,
Terminal Disclaimer ,
USPTO
It is difficult to think of a case that has had more influence on patent practice than KSR v. Teleflex (550 U.S. 398 (2007)). In KSR, the U.S. Supreme Court rejected the established practice that an invention could not be...more
7/22/2020
/ Appeals ,
Defense Strategies ,
Evidence ,
Litigation Strategies ,
Nonobvious ,
Obviousness ,
Patent Applications ,
Patent Litigation ,
Patent Prosecution ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
Prior Art ,
SCOTUS ,
USPTO
When the U.S. Food and Drug Administration approves a new drug, it also approves a package insert of the drug, known as a “product label.” A pharmaceutical company marketing a generic product is required to package their...more
On April 1, 2013, the U.S. Patent and Trademark Office (USPTO) published an interim final rule revising several patent term adjustment (PTA) provisions in view of the AIA Technical Corrections Act. 78 Fed. Reg. 19416. In...more